Our study was underpowered to examine the clinical benefit (incidence of thromboembolic stroke, recurrent DVT or PE, etc....) or clinical harm (bleeding complications) of these two warfarin dosing strategies, however TTR has been validated as a surrogate marker for clinical outcomes in the non-dialysis population [5]. Here, TTR is linked to deep vein thrombosis.